Atorvastatin calcium - Generic Drug Details

What are the generic sources for atorvastatin calcium and what is the scope of freedom to operate?

Atorvastatin calcium is the generic ingredient in five branded drugs marketed by Cmp Dev Llc, Accord Hlthcare, Alkem Labs Ltd, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Biocon Pharma, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys, Dr Reddys Labs Ltd, Graviti Pharms, Hetero Labs Ltd V, Invagen Pharms, Lannett Co Inc, Laurus, Lepu Pharm, Lupin Ltd, Macleods Pharms Ltd, Mankind Pharma, Micro Labs Ltd India, MSN, Mylan Pharms Inc, Perrigo R And D, Sciegen Pharms, Shandong Xinhua, Strides Pharma, Sun Pharm Inds Ltd, Teva Pharms, Teva Pharms Inc, Teva Pharms Usa, Umedica, Zydus Pharms, Upjohn, Organon, and Pharmobedient, and is included in thirty-seven NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atorvastatin calcium has two patent family members in two countries.

There are fifty-five drug master file entries for atorvastatin calcium. Sixty-one suppliers are listed for this compound.

Summary for atorvastatin calcium

International Patents:	2
US Patents:	5
Tradenames:	5
Applicants:	36
NDAs:	37
Drug Master File Entries:	55
Finished Product Suppliers / Packagers:	61
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	72
Patent Applications:	6,089
Drug Sales Revenues:	Drug sales revenues for atorvastatin calcium
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for atorvastatin calcium
What excipients (inactive ingredients) are in atorvastatin calcium?	atorvastatin calcium excipients list
DailyMed Link:	atorvastatin calcium at DailyMed

See drug sales revenues for atorvastatin calcium

Recent Clinical Trials for atorvastatin calcium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NewAmsterdam Pharma	Phase 1
Pharma Medica Research, Inc.	Phase 1
University of California, San Francisco	Phase 2

See all atorvastatin calcium clinical trials

Pharmacology for atorvastatin calcium

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

Medical Subject Heading (MeSH) Categories for atorvastatin calcium

Anticholesteremic Agents

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for atorvastatin calcium

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for atorvastatin calcium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Ltd	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	091650-003	Jul 17, 2012	AB	RX	No	No
Apotex Inc	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	090548-003	May 29, 2012	AB	RX	No	No
Shandong Xinhua	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	211886-001	Jan 25, 2024	AB	RX	No	No
Invagen Pharms	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	204846-004	Jan 9, 2017		DISCN	No	No
Sciegen Pharms	ATORVASTATIN CALCIUM	atorvastatin calcium	TABLET;ORAL	205519-001	May 19, 2016	AB	RX	No	No

Expired US Patents for atorvastatin calcium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-003	Dec 17, 1996	5,273,995*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	5,273,995*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	5,969,156*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-001	Dec 17, 1996	4,681,893*PED
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-002	Dec 17, 1996	5,385,929

International Patents for atorvastatin calcium

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3468606	NOUVELLE COMPOSITION PHARMACEUTIQUE DE COMPOSÉ HYPOLIPIDÉMIANT (A NOVEL PHARMACEUTICAL COMPOSITION OF A LIPID LOWERING COMPOUND)
European Patent Office	3468606
World Intellectual Property Organization (WIPO)	2017212409

Supplementary Protection Certificates for atorvastatin calcium

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1003503	30/2006	Austria		PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707
0247633	C970034	Netherlands		PRODUCT NAME: ATORVASTATINUM,DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF VAN HET INWENDIGE DELTA-LACTON, IN HET BIJZONDER ATORVASTATINUM CALCICUM TRIHYDRICUM; NAT. REGISTRATION NO/DATE: RVG 21081 - RVG 21083 19970421; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107
0720599	92545	Luxembourg		PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910
0720599	CR 2014 00050	Denmark		PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910
0247633	62/1997	Austria		PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107

Market Dynamics and Financial Trajectory for Atorvastatin Calcium

Last updated: March 18, 2026

What is the current market landscape for atorvastatin calcium?

Atorvastatin calcium is a widely prescribed statin used to lower LDL cholesterol, reduce cardiovascular risk, and prevent coronary artery disease. It is a leading generic statin with global sales exceeding $12 billion in 2022. The drug is available both as a branded product (Lipitor, now off patent in many regions) and as multiple generic formulations. The current market is marked by high competition, patent expirations, and ongoing demand driven by aging populations and rising cardiovascular disease prevalence.

How has patent expiration influenced market dynamics?

Lipitor (atorvastatin calcium) held patent protection until 2011 in the US. Its patent expiry resulted in generic entry, leading to a price decline by over 80% within two years. Generics now dominate sales, accounting for approximately 85% of the US atorvastatin market in 2022. Patent losses across other key markets, including Europe and Asia, have further amplified generic penetration.

Market Region	Patent Status for Lipitor	Year of Patent Expiry	Impact on Market Share
United States	Patented until 2011	2011	Rapid generic uptake, price decline
European Union	Patented until 2012	2012	Similar trend, increased generics
China	Patent expired in 2015	2015	Growing generic competition

What are the key market segments?

The global market is segmented into:

• Generic atorvastatin calcium: Dominates with over 85% share in value, mainly supplied by Indian and Chinese manufacturers.
• Branded formulations: Still sold at higher prices in regions with slower generic adoption.
• Combination therapies: Statins combined with ezetimibe or PCSK9 inhibitors, representing a growing niche.

How does pricing and reimbursement influence sales?

In markets like the US and Europe, pricing pressure from generics has pushed prices down significantly. In 2022, the average wholesale price (AWP) for generic atorvastatin ranged from $0.05 to $0.10 per 20 mg tablet. Reimbursement policies that favor generics lower out-of-pocket costs for patients and expand market access. However, in low- and middle-income countries, higher brand loyalty and variable reimbursement models sustain higher prices for branded versions.

What are the regulatory trends impacting the market?

Regulatory bodies increasingly encourage generic substitution and have approved multiple formulations under abbreviated pathways. Post-approval, bioequivalence studies are mandatory, with regulatory approval granted within 6-12 months in major markets. Countries have instituted policies to increase generic prescribing, which accelerates market share for low-cost options.

How does patent litigation affect the market?

Patent litigation delays generic entry in certain markets. Generic manufacturers challenge secondary patents protecting formulations or manufacturing processes. These legal strategies extend exclusivity, impacting market competition and pricing. For instance, Pfizer's litigation defending secondary patents delayed generic entry in some markets until 2015.

What is the outlook for future growth?

The global atorvastatin market is expected to decline gradually, driven by patent expiries and market saturation. However, demand will persist due to:

• Aging populations with higher cardiovascular disease risk.
• Increased awareness and screening programs.
• Growth in combination therapies that include atorvastatin.

Emerging markets are likely to see increased consumption, supported by expanding healthcare infrastructure and government initiatives. The compound annual growth rate (CAGR) for the generic atorvastatin segment is estimated at 2-4% over the next five years.

Factor	Effect on Market Trajectory
Patent expiries	Suppresses branded sales, boosts generics
Pricing pressure	Lowers revenue per unit but increases volume
Regulatory policies	Accelerate generic approval and adoption
Market saturation	Limits growth in mature regions
Emerging markets	Drive volume growth

Key financial considerations

• Revenue Decline Post-Patent Expiry: Sales for Lipitor dropped from over $10 billion in 2009 to below $1 billion annually by 2012.
• Generics Profitability: Margins are low, with typical operating margins below 10% for generic suppliers.
• Market Share Shifts: Largest generic manufacturers, such as Teva, Mylan, and Sun Pharma, hold significant portions of the market, with each holding approximately 10-15% share in 2022.
• Pricing Trends: The global average price per tablet continues to decline, with some markets experiencing reductions of 80-90% since patent expiry.

Summary Table: Financial & Market Metrics (2022)

Metric	Value
Global sales of atorvastatin	$12 billion (including all formulations)
Share of generic formulations	85% (by volume), 70% (by value)
Top generic manufacturer sales	$2 billion (annual)
Average price per 20 mg tablet	$0.05 - $0.10 in the US
Market CAGR (2022-2027)	2-4% in emerging markets

Key Takeaways

• The atorvastatin calcium market experienced a sharp decline in branded sales post-patent expiry, replaced by low-margin generics.
• Market growth now hinges on emerging markets, combination therapies, and drug adherence initiatives.
• Price competition and patent litigation shape the competitive landscape.
• Regulatory policies favor generic substitution, accelerating market penetration.
• Future revenues will be constrained by market saturation but supported by demographic trends and evolving treatment regimens.

FAQs

1. How does patent expiry generally impact atorvastatin sales?
Patent expiry leads to rapid generic entry, causing significant price drops and sales volume increases for generic manufacturers, while branded sales decline sharply.

2. What are the main competitive factors in the atorvastatin market?
Market share depends on manufacturing cost efficiency, regulatory approval speed, patent litigation outcomes, and regional reimbursement policies.

3. Are there any promising formulations or combinations involving atorvastatin?
Yes, combination therapies with ezetimibe or PCSK9 inhibitors are gaining market share, especially for patients with statin intolerance or high cardiovascular risk.

4. How do regulatory policies influence market dynamics?
Policies promoting generic substitution and bioequivalence standards expedite market entry, expanding access and reducing prices.

5. What is the potential impact of emerging markets on the atorvastatin landscape?
Emerging markets represent growth opportunities due to increasing cardiovascular disease prevalence, expanding healthcare infrastructure, and affordability of generic formulas.

---

References

[1] IQVIA Institute. (2022). The Global Use of Medicines in 2022.
[2] U.S. Food and Drug Administration. (2022). Drug Approvals and Litigation Data.
[3] MarketsandMarkets. (2023). Statins Market by Type, Application, and Region.
[4] European Medicines Agency. (2022). Guidelines on Bioequivalence.
[5] Press J. (2021). "Impact of Patent Expiry on Statin Market," Journal of Pharmaceutical Economics.